亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial

医学 安慰剂 特发性肺纤维化 耐受性 CTGF公司 内科学 人口 肺活量 外科 不利影响 病理 肺 生长因子 扩散能力 替代医学 受体 环境卫生 肺功能
作者
Luca Richeldi,Evans R. Fernández Pérez,Ulrich Costabel,Carlo Albera,David J. Lederer,Kevin R. Flaherty,Neil A. Ettinger,Rafael L. Perez,Mary Beth Scholand,Jonathan Gerald Goldin,Kin-Hung Peony Yu,Thomas B. Neff,Seth Porter,Ming Zhong,Eduard Gorina,Elias Kouchakji,Ganesh Raghu
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (1): 25-33 被引量:300
标识
DOI:10.1016/s2213-2600(19)30262-0
摘要

Summary

Background

Connective tissue growth factor (CTGF) is a secreted glycoprotein that has a central role in the process of fibrosis. This study was designed to assess the safety, tolerability, and efficacy of pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pulmonary fibrosis. The aim was to establish whether pamrevlumab could slow, stop, or reverse progression of idiopathic pulmonary fibrosis.

Methods

The phase 2, randomised, double-blind, placebo-controlled PRAISE trial was done at 39 medical centres in seven countries (Australia, Bulgaria, Canada, India, New Zealand, South Africa, and the USA). Patients with idiopathic pulmonary fibrosis and percentage of predicted forced vital capacity (FVC) of 55% or greater were enrolled and randomly assigned (1:1) by use of interactive responsive technology to intravenous infusion of pamrevlumab 30 mg/kg or placebo every 3 weeks over 48 weeks (16 infusions). The primary efficacy outcome was change from baseline in percentage of predicted FVC at week 48. Disease progression (defined as a decline from baseline in percentage of predicted FVC of ≥10%, or death) at week 48 was a key secondary efficacy outcome. All patients in the pamrevlumab group received at least one dose of the study drug and were analysed for safety. Two patients in the placebo group were excluded from the intention-to-treat population for the efficacy analyses because of enrolment error. This trial is registered with ClinicalTrials.gov, NCT01890265.

Findings

Between Aug 17, 2013, and July 21, 2017, 103 patients were randomly assigned (50 to pamrevlumab and 53 to placebo). Pamrevlumab reduced the decline in percentage of predicted FVC by 60·3% at week 48 (mean change from baseline −2·9% with pamrevlumab vs −7·2% with placebo; between-group difference 4·3% [95% CI 0·4–8·3]; p=0·033). The proportion of patients with disease progression was lower in the pamrevlumab group than in the placebo group at week 48 (10·0% vs 31·4%; p=0·013). Pamrevlumab was well tolerated, with a safety profile similar to that of placebo. Treatment-emergent serious adverse events were observed in 12 (24%) patients in the pamrevlumab group and eight (15%) in the placebo group, with three patients on pamrevlumab and seven on placebo discontinuing treatment. Of the three (6%) deaths in the pamrevlumab group and six (11%) in the placebo group, none was considered treatment related.

Interpretation

Pamrevlumab attenuated progression of idiopathic pulmonary fibrosis and was well tolerated. Now in phase 3 development, pamrevlumab shows promise as a novel, safe, and effective treatment for idiopathic pulmonary fibrosis.

Funding

FibroGen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
沉醉的中国钵完成签到 ,获得积分10
4秒前
8秒前
痴情的归尘完成签到,获得积分10
23秒前
31秒前
orixero的应助被五岁的哈士奇采纳,获得10
34秒前
43秒前
丘比特的应助被HJJHJH采纳,获得10
44秒前
小小昌发布了新的文献求助10
49秒前
柔弱的铅笔完成签到,获得积分10
55秒前
55秒前
W主任的应助被科研通管家采纳,获得10
59秒前
奔跑的应助被科研通管家采纳,获得10
59秒前
稳重仇天完成签到,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
星球日记完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
迷人白桃完成签到,获得积分10
1分钟前
bkagyin的应助被成就的明辉采纳,获得10
1分钟前
1分钟前
QingSun1发布了新的文献求助10
1分钟前
888发布了新的文献求助30
1分钟前
安详老鼠完成签到,获得积分10
1分钟前
1分钟前
Shu完成签到,获得积分10
1分钟前
情怀的应助被888采纳,获得30
1分钟前
纯情的阁完成签到,获得积分10
1分钟前
向日葵的微笑完成签到,获得积分10
1分钟前
刻苦的煎蛋完成签到,获得积分10
1分钟前
cc完成签到,获得积分10
1分钟前
希望天下0贩的0的应助被www采纳,获得30
1分钟前
一条好ham完成签到,获得积分10
1分钟前
ssgg完成签到,获得积分10
1分钟前
小绵羊完成签到,获得积分10
1分钟前
不爱写论文完成签到,获得积分10
2分钟前
香蕉觅云的应助被QingSun1采纳,获得10
2分钟前
Lynee完成签到,获得积分10
2分钟前
专注的天菱完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179873
求助须知:如何正确求助?哪些是违规求助? 9570055
关于积分的说明 21808206
捐赠科研通 7775540
什么是DOI,文献DOI怎么找? 3433157
关于科研通互助平台的介绍 2557278
邀请新用户注册赠送积分活动 2478846